The mainstay treatment for metastatic prostate cancer disease aims to reduce systemic testosterone levels, which can be achieved surgically or by chemical castration, known as androgen deprivation therapy (ADT).
|Number of pages||1|
|Publication status||Published - 2018|
|Event||19th Asia-Pacific Prostate Cancer Conference - Brisbane Convention Centre, Brisbane, Australia|
Duration: 22 Aug 2018 → 25 Aug 2018
|Conference||19th Asia-Pacific Prostate Cancer Conference|
|Abbreviated title||APPC 2018|
|Period||22/08/18 → 25/08/18|
Crowe, H., Howard, N., Pillay, B., Xiberras, P., Paterson, C., & Primeau, C. (2018). Determining the supportive care needs, and distress, of Australian men with prostate cancer receiving hormone therapy: A cross-sectional study.. 17-17. Abstract from 19th Asia-Pacific Prostate Cancer Conference, Brisbane, Australia.